Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins : an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration / B.A. Ference, C.P. Cannon, U. Landmesser, T.F. Lüscher, A.L. Catapano, K.K. Ray. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - 39:27(2018 Jul 14), pp. 2540-2545. [10.1093/eurheartj/ehx450]

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins : an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

A.L. Catapano
;
2018

Settore BIO/14 - Farmacologia
   Targeting epigenetic REPROGRamming of innate immune cells in Atherosclerosis Management and other chronic inflammatory diseases
   REPROGRAM
   EUROPEAN COMMISSION
   H2020
   667837

   Immunometabolic effects of apolipoprotein E: focus on the modulation of cholesterol metabolism in antigen presenting cells
   FONDAZIONE CARIPLO
   2015-0524
14-lug-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
ehx450.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 343.02 kB
Formato Adobe PDF
343.02 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/548873
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 117
  • ???jsp.display-item.citation.isi??? 93
social impact